BMT CTN Protocol 0704 (CALGB 100104)

A Phase III Randomized, Double-Blind Study of Maintenance Therapy With Cc-5013 (Nsc # 703813, Ind # 70116) Or Placebo Following Autologous Stem Cell Transplantation For Multiple Myeloma

Below are protocol-related documents, which may be periodically updated.

  • Protocol, #18 dated February 15, 2013
  • This study is posted on as NCT00114101
  • Key Personnel

            Protocol Chairs:

           CALGB Protocol Chair: Phil McCarthy, MD

           CALBG Protocol Chair: Kenneth Anderson, MD

           ECOG Protocol Chair: Philip Greipp, MD

           BMT CTN Protocol Chair: Sergio Giralt, MD

           Protocol Officer: Marcelo Pasquini, MD

           Alliance Regulatory Group:

  This study was closed to new patient accrual on July 2, 2009.